Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2015 Jan 28.
Published in final edited form as: J Midwifery Womens Health. 2014 Jan 28;59(1):35–42. doi: 10.1111/jmwh.12101

BEYOND LABOR: THE ROLE OF NATURAL AND SYNTHETIC OXYTOCIN IN THE TRANSITION TO MOTHERHOOD

Aleeca F Bell, Elise N Erickson, C Sue Carter
PMCID: PMC3947469  NIHMSID: NIHMS506762  PMID: 24472136

Abstract

Endogenous oxytocin is a key component in the transition to motherhood affecting molecular pathways that buffer stress reactivity, support positive mood, and regulate healthy mothering behaviors (including lactation). Synthetic oxytocin is widely used throughout labor and postpartum care in modern obstetrics. Yet research on the implications beyond labor of maternal exposure to perinatal synthetic oxytocin is rare. In this article, we review oxytocin-related biological pathways and behaviors associated with the transition to motherhood, and evidence supporting the need for further research on potential effects of intrapartum oxytocin beyond labor. We include a primer on oxytocin at the molecular level.

Keywords: oxytocin, birth, mothering, Pitocin, labor, stress, mood, postpartum depression, lactation, breastfeeding

Introduction

Consequences of routine childbirth interventions on human maternal behavior have been understudied. Synthetic oxytocin (Pitocin®, Syntocinon®) stimulates uterine smooth muscle contractility and is widely used in the United States for labor induction, augmentation, and third stage management. While the judicious use of synthetic oxytocin has many benefits, the biological and behavioral effects of synthetic oxytocin beyond the immediate clinical uses remain largely unknown. According to the U.S. Centers for Disease Control and Prevention Vital Statistics report, induction has more than doubled from 1990 (10%) to 2010 (23%).1 The best current estimate of the augmentation rate in the U.S. is 57%.2 While endogenous oxytocin is well known for its role in labor and lactation, a large body of evidence documents numerous oxytocin-mediated molecular and endocrine pathways that buffer stress reactivity, support emotional and mental well-being, and promote pro-social and bonding behavior.3, 4 These behaviors are critical for successful transition to motherhood. Given the predominance of synthetic oxytocin in clinical practice, research is needed on how synthetic oxytocin may impact the intrinsic regulation of endogenous oxytocin and subsequent oxytocin-related outcomes. In this review, we examine the hypothesis that exposure to synthetic oxytocin during childbirth may play a role in maternal stress reactivity, mood, and mothering behaviors (including lactation).

OXYTOCIN ON THE MOLECULAR LEVEL

Profound changes occur in the oxytocin system during the perinatal period.5, 6 To prevent preterm birth, oxytocin neurons are kept quiescent during pregnancy through inhibitory mechanisms. The peptide oxytocin continues to accumulate in the posterior pituitary, and at term those inhibitory mechanisms are removed for labor to occur. Oxytocin also becomes more available at term through the reduction of enzymatic activity that metabolizes oxytocin in the brain. Based on animal studies, the expression of oxytocin receptors (OTR) increases throughout pregnancy in key areas of the brain that regulate mood, stress and attachment behavior. In humans, the availability of OTR in uterine muscle also increases dramatically at term, preparing for the surges of oxytocin about to be released during birth.

The neurologic origin of oxytocin

Oxytocin is a small neuropeptide consisting of nine amino acids.7 Throughout the human lifespan, specific neurons manufacture oxytocin; these cells are abundant in distinct areas of the mammalian hypothalamus called the paraventricular and supraoptic nuclei. Oxytocin from these cells is carried to and released from the posterior pituitary gland into the circulation, and from there is distributed throughout the body. Within the central nervous system, oxytocin reaches nearly all parts of the brainstem, midbrain, cortex, and spinal column. In addition to hypothalamic production, peripheral organs and tissues also may secrete oxytocin, but the pituitary is believed to be the predominant source of oxytocin in circulation.7

Oxytocin receptor: how oxytocin affects physiology in the brain and body

To affect target tissues, a receptor must be present and oxytocin presumably must bind to that receptor before it can exert cellular action. Oxytocin receptors (OTR) are found throughout the body, with particularly high concentrations in the limbic regions of the brain, spinal column, heart, intestines, immune tissue, uterus, and breast. The OTR belongs to a large family of receptors called G-protein coupled receptors, manufactured by the cell and inserted into the cell membrane where they are available for hormone-binding.7 G-protein Coupled Receptors loop in and out of the cell membrane seven times and are coupled to a G-protein located on the inside of the cell. Many varieties of G-proteins are known, each initiating a different cascade of events (second messengers) within the cell, which provides specificity to the hormone’s action. The OTR is coupled to a G-qα. This type of G-protein leads to a rise in intracellular calcium (Ca+) and a muscle cell contraction, of particular importance to milk let-down and uterine contractions (see Figure 1).7, 8

Figure 1.

Figure 1

However, when the OTR is on a neuron, the response may be the subsequent release or inhibition of other hormonal neurotransmitters and modulators, such as serotonin, endogenous opioids and corticotrophin-releasing factor.3 These nervous system interactions are key to understanding how oxytocin released in the brain influences a variety of mental states and behavior. It may also help to explain how the nervous system is stimulated in response to a human or animal’s environment (both external and internal) and subsequently leads to the release or inhibition of oxytocin. Additionally, oxytocin binds to other types of receptors, such as vasopressin receptors exerting agonist or antagonist effects, thus extending and diversifying the consequences of oxytocin’s actions.

Oxytocin-mediated pathways beyond muscle contraction

Within all cells, not just neurons, three other important functions of the OTR lead to an array of possible cellular actions. 1) Through intracellular G-protein activation, phospholipase C causes an even greater amount of Ca+ release into the cell from internal stores. This Ca+ can serve as an independent signal for various functions within the cell, especially nerves. 2) Another function is the creation of eicosanoids or prostaglandin that can directly increase pain, inflammation, and likely uterine contraction as well. 3) Thirdly, OTR activation may lead to a broad category of cellular events by activating a specific kinase, an enzyme that catalyzes the addition of a phosphate group on a specific target molecule or protein. In this instance, protein kinase C is activated and requires Ca+. The “downstream” effects of OTR activation will depend on what type of cell the receptor is located on. This kinase may initiate a specific action itself or cause another kinase to activate, and then another, creating a literal cascade of events.7 These events can ultimately lead to modifying gene transcription, regulation of the cell cycle, apoptosis and/or neurogenesis. The end result for each oxytocin-initiated pathway depends on the type of cell involved (uterine, brain, heart etc.) and the type of response initiated within that cell. OTR activation has the potential for inducing long-lasting biological alterations.

CHALLENGES IN STUDYING OXYTOCIN ON THE MOLECULAR LEVEL—BRAIN VERSUS BODY

In the intrapartum setting, the half-life of Pitocin® is believed to be only a few minutes,9 and intrapartum plasma levels correlate with Pitocin® dose and rate of administration,10 yet the dose delivered intravenously may or may not result in an effective uterine contraction pattern. Similarly, oxytocin levels in plasma cannot always be interpreted as being meaningful in a particular effect on brain activity. In order to understand how perinatal oxytocin exposure has the potential for lasting biologic consequence, it is helpful to understand some of the constraints that can limit research or the interpretation of research in this field. Many research studies examining endogenous oxytocin in animals and humans rely on blood measurement of the hormone in response to a treatment or intervention, e.g. a stressful event or a social interaction. There are several challenges in the interpretation of these measurements.

Firstly, central nervous system oxytocin is secreted continuously acting within the brain and spinal cord, but oxytocin is also released in pulses into the bloodstream through the posterior pituitary. Pulsatile release of oxytocin occurs when oxytocin neurons of the posterior pituitary depolarize, which are usually in response to specific stimuli (e.g., uterine stimuli or cues from an infant).11, 12 This activation of neurons pulses oxytocin into the blood stream. Data collected in rats suggest correlations between endogenous peripheral (blood stream) and central oxytocin levels, although the degree and significance of these correlations vary.13

In addition, there is controversy regarding whether peripherally administered oxytocin (i.e. Pitocin® given intravenously or intramuscularly) crosses the blood-brain barrier. Whether any oxytocin that does cross changes neuronal action significantly within the nervous system has yet to be determined.14 In theory, oxytocin cannot pharmacologically cross due to its relatively large size and hydrophilic nature, however, some animal studies do report low levels of oxytocin found in the brain following administration in blood15 Interestingly, some electrophysiology-based animal studies suggest that maternal oxytocin plays a neuroprotective role within the fetal brain during the birth process, which means it would have to cross both the placental barrier and fetal blood-brain barrier.16 The findings from these studies suggest that maternal oxytocin inhibits certain excitatory (GABA) fetal neurons from firing (depolarizing), thereby protecting them during periods of hypoxia (i.e. birth process). However, whether or not synthetic or endogenous oxytocin penetrates the maternal brain directly has yet to be proven. While oxytocin does leave the posterior pituitary and is released into circulation, this occurs following neuronal activation (action potential). Getting the peripherally circulating hormone into the brain would require either 1) an active transport mechanism to penetrate the tight junctions guarding the microvasculature of the central nervous system (which has yet to be proven), or 2) it would require a more porous barrier to allow for diffusion.17 The blood-brain barrier (maternal or fetal) may become more porous in states of illness or stress.

Lastly, the brain may receive information about peripheral levels of oxytocin through feedback from peripheral nervous system. Peripheral nerves may communicate information about oxytocin levels to the brain, presumably via a feedback loop (e.g. cervical dilation, adrenal gland activity, touch/ nipple stimulation). There are also well-studied effects of intranasal administration of synthetic oxytocin on mood and social behavior, yet it remains unknown whether the intranasal route allows oxytocin to enter the brain directly or extraneuronally, or whether it stimulates feed forward effects on endogenous oxytocin via ascending or afferent neuropathways (i.e. the vagus or 10th cranial nerve), which are well known to have OTRs.14 18 Peripheral feedback effects of oxytocin, which may be relayed to the brain, are difficult to monitor, but further complicate the study of synthetic oxytocin. Whether the maternal brain will reliably respond to exogenous oxytocin by decreasing or increasing the synthesis or release of endogenous oxytocin is unknown. In the clinical setting, this type of feedback might be seen when Pitocin® is used to initiate an induction of labor but then can sometimes be shut off while the woman continues to labor without the drug. Likely, feedback from peripheral nerves messaging about cervical dilation to the brain is in action, which promotes the woman’s endogenous oxytocin release, and this is more probable than the idea that Pitocin® penetrates the maternal brain directly.

However, given all these variables, altered maternal plasma levels persisting beyond the end of labor have been suggested in one study that evaluated postpartum oxytocin levels in response to breastfeeding two days after birth in women who had different intrapartum and postpartum exposures to synthetic oxytocin (n=40).19 Compared to all other study groups, women exposed to Pitocin® in labor combined with an epidural demonstrated significantly lower oxytocin levels during breastfeeding. Overall, the total quantity of synthetic oxytocin administered during parturition was negatively correlated to levels of oxytocin in plasma two days following birth. All of these women had vaginal births and newborns had normal Apgar scores. In these studies the mean duration of labor did not differ significantly between groups, nor did blood loss, or newborn weight. The women all initiated breastfeeding within minutes of birth and had the same average number of feeds in the days prior to the blood sampling. If replicable, this finding suggests that in some cases exposure to Pitocin® may have maternal consequences that last beyond the birth experience.

Altering the oxytocin receptor could change how oxytocin works

As reviewed above, the OTR must be present for oxytocin to exert its action. An important consideration for whether synthetic oxytocin may affect maternal physiology is the capacity of the OTR to become saturated. In response to saturation, sometimes a receptor is internalized, (i.e., removed from the cell-membrane where it is presumed to be unavailable and potentially degraded). In the presence of high levels of an agonist, receptor internalization may begin within minutes. The reverse process has been shown to take approximately four hours to resensitize after the agonist is removed.20 However, work on sensitization has focused on myometrial cells, studied in vitro, and it is unknown if OTR on neurons will internalize and resensitize on the cell membrane in vivo. If neuronal OTRs undergo a comparable process, this could have implications for maternal behavior.

Another strategy against saturation is that receptors may be internalized and then down-regulated, through a pause in mRNA gene transcription for the receptor.20 Research on induced labor in humans has focused on sampling the myometrium for expression of the OTR gene.21 One example is a study that compared women in spontaneous labor with those undergoing an induction of labor and 29 women who planned elective cesarean delivery. Eighteen of the 33 women in the spontaneous group eventually received augmentation with synthetic oxytocin while 26 of 30 women of the induced group did as well. All laboring participants underwent cesarean delivery (indicated for failure to progress or fetal intolerance to labor) and the myometrium was sampled at that time. Oxytocin binding, as well as mRNA levels of the OTR, was significantly affected by use of synthetic oxytocin. Participants with oxytocin-induced labor had a 300-fold down-regulation of the OTR gene in uterine muscle, when compared to receptor availability in spontaneous labor.21 This study suggests that the OTR can down-regulate in the uterus during augmented or induced labor, and points to the need to study oxytocin binding in other areas of the body such as the maternal brain, breast, heart, intestine or immune system. Whether “active management” of third stage of labor also results in down-regulation of receptors has not been reported, but given the prevalence of this practice, it deserves consideration.

The duration of mRNA down-regulation in the OTR in response to synthetic oxytocin is not yet known. Considering the cellular mechanism for receptor regeneration would include mRNA transcription, translation, protein assembly/folding and transport to the cell membrane, this could take many more hours than simple internalization of the receptor, and full restoration of a functional OTR might require days. Also, after a given tissue is no longer exposed to a saturating agonist (labor), and if there is no stimuli for releasing endogenous oxytocin (e.g. touch, breastfeeding), the response to the perceived “need” of the system may be different between different types of birth and postpartum experiences.

The role of epigenetic regulation of the OTR

On a more long-term level, receptor regulation also can occur at the level of gene transcription for the receptor through epigenetic modulation. For example, methylation is one mechanism through which gene expression is down regulated. Attachment of a methyl group (CH3) can occur on specific sites along the DNA sequence. A receptor gene that is more heavily methylated selectively “silences” the gene, preventing activation for transcription. Methylation of the OTR gene is one example of a mechanism that can down-regulate OTR gene expression, with effects that may be heritable. For example, if the OTR gene is silenced, less OTR will be available on the cell membrane. In turn, the OTR is less available to bind with oxytocin potentially resulting in diminished biological and behavioral outcomes.20

There are sensitive periods during mammalian development in which the environment can shape DNA methylation.22 For instance, rodent models show that early maternal care can be linked to patterns of methylation in both maternal and offspring phenotypes with a transgenerational effect.23 Emerging evidence supports the hypothesis that epigenetic modification of the OTR has a role in social cognition, stress reactivity, and social behavioral disorders.24 For example, one study has examined the role of methylation of the OTR in autism-affected persons. Hypermethylation of the region of DNA controlling the OTR was seen in blood samples of affected individuals compared to controls (n=20 matched pairs). This effect also was demonstrated in postmortem brain sampling of 8 matched patient-controls, showing a correlation between brain and blood methylation in the OTR.25 Pilot data in rodents suggest that normal birth with endogenous oxytocin, as well as exposure to intrapartum synthetic oxytocin, may produce epigenetic modulation of the OTR by increasing methylation of sites in the OTR gene of the maternal hypothalamus.26

OXYTOCIN AND TRANSITION TO MOTHERHOOD

The experience of giving birth and becoming a mother, particularly for the first time, demands a high level of physical and social interaction. Being able to sensitively care for the needs of the infant through synchronous mother-infant interaction is vital to the continuation of the family and species. The postpartum period is also characterized by drastic hormonal shifts, transition to motherhood, coping with new stressors, physical pain, lactation and attachment - all of which involve the endogenous oxytocin system. Furthermore, modern parenting can include financial strains, work obligations, social isolation or limited support, and socio-cultural constructs about “good” mothering. Within this context, a difficult transition to motherhood holds the potential to lead to dysregulated stress reactivity, mood disturbances, susceptibility to less sensitive mothering, asynchronous mother-infant interaction, and poor infant attachment.

Stress Reactivity

The maternal brain is a distinctive biological state, characterized by a host of biochemical mechanisms supporting the well-being and survival of both mother and infant.6 Significant adaptations occur in the maternal oxytocin system, including protection from the stress and demands of the perinatal period The dramatic rise of oxytocin during physiologic birth may play a role in buffering the stress hormones released by fear and pain during labor according to animal studies and some human work.27 This adaptive response is likely a protective mechanism during the perinatal period, a time of intense stress.

The relationship between oxytocin and the HPA (hypothalamic-pituitary-adrenal) axis in the body’s response to stressful stimuli has been investigated primarily using rodent models.3 These demonstrate that pregnant animals have reduced reactivity to stressors via lowered plasma levels of corticotrophin releasing factor, adrenocorticotropin releasing factor, and cortisol. There is inhibition of both oxytocin and HPA neurons during pregnancy mainly due to an inhibitory opioid mechanism from increased allopregnanolone (a metabolite of progesterone).6 During lactation, oxytocin pulses in the brain increase and the hormone is secreted into circulation. Meanwhile brain levels of oxytocin also increase and influence the neurons linked to the stress response system. Lactating females react less to stressors and display less anxiety-like behavior than non-lactating females. In response to stress oxytocin increases, possibly as a protective mechanism against continued stress. This can be seen when cortisol and adrenocorticotropin releasing factor decrease after administration of synthetic oxytocin. Conversely, when an oxytocin antagonist is given to rats, their levels of cortisol increase. However, in humans the relationships among oxytocin, HPA function, and stress reactivity are less well characterized. Measurements of salivary oxytocin in lactating women suggest that oxytocin may increase prior to feeding, when women are preparing to breastfeed.11 There is also a decrease in circulating HPA hormones immediately after breastfeeding is initiated. Likely this is due to oxytocin within the brain exerting an effect on neurons that activate the HPA axis and corticotrophin releasing factor. Lactating women show increased vagal tone, decreased blood pressure and decreased heart rate when compared to non-lactating women, especially in response to a stressor.28 As discussed earlier the vagus nerve detects elevated levels of oxytocin within the body and can feedback to the brain via afferent pathways. There is increasing evidence of a role for oxytocin in buffering stress reactivity, suggesting that oxytocin and the HPA systems are intricately linked.27

Maternal Mood

As with stress reactivity, a well-regulated oxytocin system is anxiolytic and confers protection against negative mood. Several studies have shown that intranasal administration of synthetic oxytocin has an anxiolytic effect in psychiatric disorders.14 Whether intrapartum synthetic oxytocin confers the same protective function as endogenous oxytocin on maternal mental health is more difficult to determine, especially in light of the complexity of contemporary birth practices. Maternal depression in the postpartum period is estimated to affect up to 19% of women.29 Women experiencing negative mood are less likely to show positive mothering behaviors, and are less sensitive to infant needs.30 The decreased quality of mother-infant interaction may lead to suboptimal infant attachment,31 placing infants at risk for poor development.32

While there are well-known predictors of postpartum negative mood (e.g., poor social support, stressful/adverse life events, and history of depression/anxiety), subjective and objective birth variables (i.e., complications, mode of delivery, increased use of interventions, and maternal perception of the experience) also may be predictors of maternal outcome.33, 34 However, little is known of the biological underpinnings linking birth variables to postpartum mood, the specific effect of exposure to synthetic oxytocin has not been teased apart. Use of synthetic oxytocin is often associated with preexisting complications, but even in low-risk situations synthetic oxytocin can precipitate a cascade of interventions and subsequent birth complications.35 Whether exposure to synthetic oxytocin during childbirth affects postpartum mood is unknown. However, based on our knowledge of the actions of oxytocin in other situations and in tissues outside of the central nervous system, we would anticipate that any effects of synthetic oxytocin would be dose-dependent and would show individual differences, influenced by context and the history of the mother.36

Rodent models can elucidate molecular pathways of mood that have been evolutionarily conserved in mammals.37 For instance, serotonin and dopamine are mediators of oxytocin’s anxiolytic actions in both humans and rodents. When endogenous oxytocin is genetically or pharmacologically blocked, anxiety-like and depression-like behavior increases in oxytocin-deficient knockout mice compared to wild-type mice.38 In responding to a stressor, rats bred for “high anxiety” exhibit a higher release of central oxytocin and greater anxiety-like and depression-like symptoms than rats bred for “low anxiety”.39 Oxytocin is one of the evolutionarily conserved molecular pathways of mood.

In humans, numerous studies have found that atypical peripheral oxytocin levels (very high or very low) may be associated with elevated symptoms of depression, anxiety, or post-traumatic stress.40 In one perinatal example (n=74), low levels of oxytocin in late pregnancy were associated with elevated symptoms of depression at two weeks postpartum, controlling for prepartum symptoms, socio-demographics, and birth-outcomes.41 Individual context, adversities across the life cycle, history of trauma, genotype, and epigenetic processes are all factors that may program the oxytocin system altering (and possibly increasing) sensitivity to synthetic oxytocin during childbirth.

Mothering Behaviors

Endogenous oxytocin’s role in mediating the initiation of maternal behavior has been demonstrated in numerous nonhuman species. Perinatal manipulation of the oxytocin system in animals provides strong evidence of subsequent dysfunctional maternal behaviors.4246 For instance, in rats, oxytocin clearly mediates the initiation of maternal behavior.44 In ewes, maternal acceptance of their own lamb occurs after identification, yet a central injection of synthetic oxytocin can promote maternal acceptance of alien lambs.43 Optimal maternal behavior is blocked in ewes and heifers when central oxytocin is not released in physiologic birth due to regional anesthesia and subsequent lack of vagino-cervical stimulation.46 In nonhuman primates, optimal maternal behavior can be altered by a central injection of synthetic oxytocin or by an oxytocin antagonist.42, 45

One particular animal model has been useful in understanding the role of oxytocin in forming social bonds. The socially monogamous prairie vole forms pair bonds, an uncommon phenomenon among rodents of the opposite sex. It is postulated that the role of oxytocin buffers stress-reactivity as a function of social interaction and bonding.4 Research with this model points to the possibility of altering social behavior as a function of exposure to synthetic oxytocin early in life. For example, in prairie vole pups, exposure to synthetic oxytocin on the first day of life had lasting and dose-dependent effects on the capacity to form pair bonds in later life. In this model, exposure to a low dose of synthetic oxytocin facilitated pair bonding later in that pup’s life, while exposure to a high dose inhibited pair bond formation.47 Exposure to an oxytocin antagonist in the same time period inhibited subsequent social behaviors including the typical willingness to care for unrelated infants (alloparenting), possibly mediated by increases in anxiety.47 In addition, physiologic birth itself may be critical in the initiation of prairie vole maternal behavior. Female voles delivered by cesarean surgery have demonstrated infanticidal behavior; while females delivered vaginally (and that underwent a sham surgery following birth) did not.48

A growing body of evidence suggests a link between oxytocin and optimal mothering behaviors in humans as well.4953 Optimal mothering behaviors include affectionate touch, eye-to-eye contact, positive affect, and affectionate language that are characterized by sensitivity to infant cues and synchronous mother-infant interaction.50 Synchronicity in mother-infant interaction has a strong effect on infant affective states. Numerous studies have found an association between atypical peripheral oxytocin levels and less optimal mothering behavior.50 Genetic variation (i.e., risk alleles), and decreased central binding, of the OTR gene have also been associated with less optimal mothering behavior.49, 51, 52 A recent fMRI study of 15 parent-infant dyads found two distinct brain -behavior-oxytocin profiles in mothers displaying synchronous versus intrusive mothering behavior.53 Mothers who displayed synchronicity in mother-infant interaction, had plasma oxytocin levels correlating with neural organization in reward-related motivational areas of the brain (left nucleus accumbens and right amygdala). In contrast, mothers who displayed intrusiveness in mother-infant interaction had no significant correlation between activation of neural reward areas and oxytocin levels. Additionally, the role of oxytocin in mothering behavior has been linked with the woman’s affiliative experiences throughout her life (e.g., her own parents, partner and infant).54 Again, it is unclear if any of these relationships are derived or influenced by the birth experience, or use of synthetic oxytocin. However, these findings do suggest that oxytocin plays a key role, beyond labor, in the transition to motherhood.

Lactation

The physiological transition to motherhood also includes establishing lactation. A few recent studies have examined lactation in the context of synthetic oxytocin and use of epidural anesthesia. For example, in Sweden 351 women who received an epidural were case-control matched with 351 women who did not receive an epidural.55 Breastfeeding success was negatively associated with epidural use. Importantly, women who were augmented with synthetic oxytocin were three times less likely to initiate breastfeeding in the first four hours, and two times more likely to give artificial milk by the time of hospital discharge. Another small study (n=20) examined breastfeeding duration in relationship to intrapartum exposure to synthetic oxytocin during induction or augmentation of labor. All mothers had epidural anesthesia. Authors reported an inverse relationship between synthetic oxytocin dose and a shorter duration of exclusive breastfeeding by 3 months.56

Consequences for the offspring

Evidence for long-term negative consequences for social behavior and the management of stressful experiences have repeatedly appeared in animal studies of offspring exposed to manipulations by oxytocin in early life. For example, work in piglets revealed that exposure to intranasal oxytocin in early life produced atypical, nonreciprocal social behavior and an altered capacity to respond to stressful experiences in later life.57 Several studies in rodents similarly support the hypothesis that exposure to synthetic oxytocin, especially at high levels, during the perinatal period can have effects on the offspring.4

Studies of the long-term consequences of perinatal oxytocin exposure for children are less common. However, authors recently reported - based on a study in New York City of 3000 full term infants - that Pitocin®-treated infants showed an increase in multiple “adverse outcomes” including reductions in Apgar scores (indexed by increased pulse, breathing rate and “reflex irritability”) and increased admission to the NICU.58 Increased admission to the NICU and other adverse effects, with an estimated 30% increase in measures of morbidity, also were seen in a 2012 study from Australia.59 Neurodevelopmental risk for the offspring also was suggested by the finding that the occurrence of attention deficit disorders was twice as likely in children exposed to Pitocin® during birth.60

Several studies have linked exposure to synthetic oxytocin to reductions in lactation, and diminished feeding-related behavior in the newborn.56, 61 These studies underscore the need for further research, especially taken in the context of a growing experimental literature in animals linking long-term behavioral outcomes to exposure to synthetic oxytocin in the perinatal period.

CONCLUSION

Oxytocin is a neuroendocrine hormone with complex actions throughout the body and effects vital to the mother-infant dyad and social well-being. Much remains to be understood about the role oxytocin plays in the transition to motherhood; however, emerging research in both animal and human models highlights the need for a deeper understanding of the role of physiologic birth in mother-infant biobehavioral outcomes important to the disciplines of midwifery and obstetrics.

Clearly, the role of oxytocin in the body extends far beyond uterine contractility to molecular cell systems that have potential long-term consequences. Downstream molecular effects of naturally-expressed oxytocin and synthetic oxytocin have not been investigated thoroughly in the context of human birth care. Midwifery and obstetric research should consider the oxytocin system as a whole, not just the immediate clinical result, when investigating the role of physiologic birth as well as birth interventions on biobehavioral outcomes in mothers and infants.

Research questions abound regarding the long-term implications of manipulating the oxytocin system during childbirth - an intricate transitional window of time for both mother and infant. One example may be early identification of women at-risk for postpartum mood disorders or lactation difficulties. Identifying at-risk women could potentially be informed by the interaction of OTR genotype, OTR epigenotype, and differential birth experiences impacting the regulation of endogenous oxytocin.

While many basic questions remain, we suggest that birth practitioners may benefit from an appreciation of the molecular, developmental and behavioral consequences of one of the most widely used drugs in obstetric practice. Given the lack of clarity and definitive research on the effects of oxytocin beyond labor, the dedication of health care professionals to minimal-interference in biologically-regulated and evolutionarily-conserved processes is warranted. There is great potential for interdisciplinary collaboration as the ubiquitous use of synthetic oxytocin in modern birth continues.

Quick Points.

  • Downstream molecular effects of synthetic oxytocin have rarely been investigated in the context of human birth care.

  • The role of natural oxytocin includes molecular pathways in the transition to motherhood, such as buffering stress reactivity, supporting positive mood and regulating healthy mothering behaviors.

  • Given the action of natural oxytocin on various endocrine pathways, we anticipate that any effects of intrapartum synthetic oxytocin would be dose-dependent and influenced by individual context and maternal history.

  • With the ubiquitous use of synthetic oxytocin in modern birth care, research questions abound regarding long-term implications of manipulating the oxytocin system during labor – a complex transitional window of development for both mother and infant.

Acknowledgments

This original review was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000050. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

We thank The Fetzer Institute for their generous support of research on optimal birth

Biographies

Aleeca F. Bell, PhD, CNM, is an Assistant Professor at the University of Illinois at Chicago, College of Nursing, Chicago, Illinois, and also a Center for Clinical and Translational Science KL2 Scholar.

Elise Erickson, CNM, MSN, is in clinical practice as a Certified Nurse Midwife and Clinical Supervisor at Columbia Women's Clinic, Providence Medical Group in Portland, Oregon.

C. Sue Carter, PhD, is Research Professor in the Department of Psychiatry, University of North Carolina, Chapel Hill, NC 27599

Footnotes

Conflict of interest disclosure:

The authors report no conflicts of interest.

References

  • 1.Martin JA, Hamilton BE, Ventura SJ, Osterman MJK, Wilson TJ, Mathews T. Births: Final data for 2010. In: Reports NVS, editor. Hyatttsville, MD: National Center for Health Statistics; 2012. [PubMed] [Google Scholar]
  • 2.Declercq ER, Sakala C, Corry MP. Listening to mothers II: report of the second national U.S. survey of women's childbearing experiences. New York: Childbirth Connection; 2006. Executive summary. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Neumann ID, Landgraf R. Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci. 2012;35(11):649–659. doi: 10.1016/j.tins.2012.08.004. [DOI] [PubMed] [Google Scholar]
  • 4.Carter CS, Boone EM, Pournajafi-Nazarloo H, Bales KL. Consequences of early experiences and exposure to oxytocin and vasopressin are sexually dimorphic. Dev Neurosci. 2009;31(4):332–341. doi: 10.1159/000216544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Brunton PJ, Russell JA. Endocrine induced changes in brain function during pregnancy. Brain Res. 2010;1364:198–215. doi: 10.1016/j.brainres.2010.09.062. [DOI] [PubMed] [Google Scholar]
  • 6.Brunton PJ, Russell JA. The expectant brain: adapting for motherhood. Nat rev Neurosci. 2008;9(1):11–25. doi: 10.1038/nrn2280. [DOI] [PubMed] [Google Scholar]
  • 7.Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81(2):629–683. doi: 10.1152/physrev.2001.81.2.629. [DOI] [PubMed] [Google Scholar]
  • 8.Devost D, Wrzal P, Zingg HH. Oxytocin receptor signalling. Prog Brain Res. 2008;170:167–176. doi: 10.1016/S0079-6123(08)00415-9. [DOI] [PubMed] [Google Scholar]
  • 9.Arias F. Pharmacology of oxytocin and prostaglandins. Clin Obstet Gynecol. 2000;43(3):455–468. doi: 10.1097/00003081-200009000-00006. [DOI] [PubMed] [Google Scholar]
  • 10.Perry RL, Satin AJ, Barth WH, Valtier S, Cody JT, Hankins GD. The pharmacokenetics of oxytocin as they apply to labor induction. Am J Obstet Gynecol. 1996;174(5):1590–1593. doi: 10.1016/s0002-9378(96)70611-7. [DOI] [PubMed] [Google Scholar]
  • 11.White-Traut R, Watanabe K, Pournajafi-Nazarloo H, Schwertz D, Bell A, Carter CS. Detection of salivary oxytocin levels in lactating women. Dev Psychobiol. 2009;51(4):367–373. doi: 10.1002/dev.20376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Israel JM, Poulain DA, Oliet SH. Oxytocin-induced postinhibitory rebound firing facilitates bursting activity in oxytocin neurons. J Neurosci. 2008;28(2):385–394. doi: 10.1523/JNEUROSCI.5198-07.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Neumann ID, Torner L, Toschi N, Veenema AH. Oxytocin actions within the supraoptic and paraventricular nuclei: differential effects on peripheral and intranuclear vasopressin release. Am J Physiol Regul Integr Comp Physiol. 2006 doi: 10.1152/ajpregu.00763.2005. [DOI] [PubMed] [Google Scholar]
  • 14.Churchland PS, Winkielman P. Modulating social behavior with oxytocin: how does it work? What does it mean? Horm Behav. 2012;61(3):392–399. doi: 10.1016/j.yhbeh.2011.12.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Ermisch A, Barth T, Ruhle HJ, Skopkova J, Hrbas P, Landgraf R. On the blood-brain barrier to peptides: accumulation of labelled vasopressin, DesGlyNH2-vasopressin and oxytocin by brain regions. Endocrinol Exp. 1985;19(1):29–37. [PubMed] [Google Scholar]
  • 16.Khazipov R, Tyzio R, Ben-Ari Y. Effects of oxytocin on GABA signalling in the foetal brain during delivery. Prog Brain Res. 2008;170:243–257. doi: 10.1016/S0079-6123(08)00421-4. [DOI] [PubMed] [Google Scholar]
  • 17.McEwen BB. Brain-fluid barriers: relevance for theoretical controversies regarding vasopressin and oxytocin memory research. Adv Pharmacol. 2004;50:531–592. 655–708. doi: 10.1016/S1054-3589(04)50014-5. [DOI] [PubMed] [Google Scholar]
  • 18.Uvnas-Moberg K. Role of efferent and afferent vagal nerve activity during reproduction: integrating function of oxytocin on metabolism and behaviour. Psychoneuroendocrinology. 1994;19(5–7):687–695. doi: 10.1016/0306-4530(94)90050-7. [DOI] [PubMed] [Google Scholar]
  • 19.Jonas K, Johansson LM, Nissen E, Ejdeback M, Ransjo-Arvidson AB, Uvnas-Moberg K. Effects of intrapartum oxytocin administration and epidural analgesia on the concentration of plasma oxytocin and prolactin, in response to suckling during the second day postpartum. Breastfeed Med. 2009;4(2):71–82. doi: 10.1089/bfm.2008.0002. [DOI] [PubMed] [Google Scholar]
  • 20.Kimura T, Saji F, Nishimori K, Ogita K, Nakamura H, Koyama M, et al. Molecular regulation of the oxytocin receptor in peripheral organs. J Mol Endocrinol. 2003;30(2):109–115. doi: 10.1677/jme.0.0300109. [DOI] [PubMed] [Google Scholar]
  • 21.Phaneuf S, Rodriguez Linares B, TambyRaja RL, MacKenzie IZ, Lopez Bernal A. Loss of myometrial oxytocin receptors during oxytocin-induced and oxytocin-augmented labour. J Reprod Fertil. 2000;120(1):91–97. doi: 10.1530/jrf.0.1200091. [DOI] [PubMed] [Google Scholar]
  • 22.Heim C, Binder EB. Current research trends in early life stress and depression: Review of human studies on sensitive periods, gene-environment interactions, and epigenetics. Exp Neurol. 2012;233(1):102–111. doi: 10.1016/j.expneurol.2011.10.032. [DOI] [PubMed] [Google Scholar]
  • 23.Szyf M, McGowan P, Meaney M. The social environment and the epigenome. Environ Mol Mutagen. 2008;49(1):46–60. doi: 10.1002/em.20357. [DOI] [PubMed] [Google Scholar]
  • 24.Kumsta R, Hummel E, Chen FS, Heinrichs M. Epigenetic regulation of the oxytocin receptor gene: implications for behavioral neuroscience. Front Neurosci. 2013;7:83. doi: 10.3389/fnins.2013.00083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Gregory SG, Connelly JJ, Towers AJ, Johnson J, Biscocho D, Markunas CA, et al. Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. BMC Med. 2009;7:62. doi: 10.1186/1741-7015-7-62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Connelly JJ, Kenkel W, Erickson E, Carter CS. Society for Neuroscience. Washington D.C.: 2011. Are birth and oxytocin epigenetic events? [Google Scholar]
  • 27.Carter CS, Altemus M, Chrousos GP. Neuroendocrine and emotional changes in the post-partum period. Prog Brain Res. 2001;133:241–249. doi: 10.1016/s0079-6123(01)33018-2. [DOI] [PubMed] [Google Scholar]
  • 28.Altemus M, Redwine LS, Leong YM, Frye CA, Porges SW, Carter CS. Responses to laboratory psychosocial stress in postpartum women. Psychosom Med. 2001;63(5):814–821. doi: 10.1097/00006842-200109000-00015. [DOI] [PubMed] [Google Scholar]
  • 29.O'Hara MW, McCabe JE. Postpartum depression: current status and future directions. Annu Rev Clin Psychol. 2013;9:379–407. doi: 10.1146/annurev-clinpsy-050212-185612. [DOI] [PubMed] [Google Scholar]
  • 30.Shin H, Park YJ, Ryu H, Seomun GA. Maternal sensitivity: A concept analysis. J Adv Nurs. 2008;64(3):304–314. doi: 10.1111/j.1365-2648.2008.04814.x. [DOI] [PubMed] [Google Scholar]
  • 31.Beck CT. The effects of postpartum depression on maternal-infant interaction: A meta-analysis. Nurs Res. 1995;44(5):298–304. [PubMed] [Google Scholar]
  • 32.Kingston D, Tough S, Whitfield H. Prenatal and postpartum maternal psychological distress and infant development: a systematic review. Child Psychiatry Hum Dev. 2012;43(5):683–714. doi: 10.1007/s10578-012-0291-4. [DOI] [PubMed] [Google Scholar]
  • 33.Blom EA, Jansen PW, Verhulst FC, Hofman A, Raat H, Jaddoe VW, et al. Perinatal complications increase the risk of postpartum depression. The Generation R Study. BJOG. 2010;117(11):1390–1398. doi: 10.1111/j.1471-0528.2010.02660.x. [DOI] [PubMed] [Google Scholar]
  • 34.Waldenstrom U, Hildingsson I, Rubertsson C, Radestad I. A negative birth experience: Prevalence and risk factors in a national sample. Birth. 2004;31(1):17–27. doi: 10.1111/j.0730-7659.2004.0270.x. [DOI] [PubMed] [Google Scholar]
  • 35.Sakala C, Corry M. Evidence-based maternity care: What it is and what can be achieved. New York: Childbirth Connections, Reforming States Group, and Milbank Memorial Fund; 2008. [Google Scholar]
  • 36.Bartz JA, Zaki J, Bolger N, Ochsner KN. Social effects of oxytocin in humans: context and person matter. Trends Cogn Sci. 2011;15(7):301–309. doi: 10.1016/j.tics.2011.05.002. [DOI] [PubMed] [Google Scholar]
  • 37.Yan HC, Cao X, Das M, Zhu XH, Gao TM. Behavioral animal models of depression. Neuroscience bulletin. 2010;26(4):327–337. doi: 10.1007/s12264-010-0323-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Amico JA, Mantella RC, Vollmer RR, Li X. Anxiety and stress responses in female oxytocin deficient mice. J Neuroendocrinol. 2004;16(4):319–324. doi: 10.1111/j.0953-8194.2004.01161.x. [DOI] [PubMed] [Google Scholar]
  • 39.Bosch OJ, Meddle SL, Beiderbeck DI, Douglas AJ, Neumann ID. Brain oxytocin correlates with maternal aggression: link to anxiety. J Neurosci. 2005;25(29):6807–6815. doi: 10.1523/JNEUROSCI.1342-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Cyranowski JM, Hofkens TL, Frank E, Seltman H, Cai HM, Amico JA. Evidence of dysregulated peripheral oxytocin release among depressed women. Psychosom Med. 2008;70(9):967–975. doi: 10.1097/PSY.0b013e318188ade4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Skrundz M, Bolten M, Nast I, Hellhammer DH, Meinlschmidt G. Plasma oxytocin concentration during pregnancy is associated with development of postpartum depression. Neuropsychopharmacology. 2011;36(9):1886–1893. doi: 10.1038/npp.2011.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Boccia ML, Goursaud AP, Bachevalier J, Anderson KD, Pedersen CA. Peripherally administered non-peptide oxytocin antagonist, L368,899, accumulates in limbic brain areas: a new pharmacological tool for the study of social motivation in non-human primates. Horm Behav. 2007;52(3):344–351. doi: 10.1016/j.yhbeh.2007.05.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Keverne EB, Kendrick KM. Oxytocin facilitation of maternal behavior in sheep. Ann N Y Acad Sci. 1992;652:83–101. doi: 10.1111/j.1749-6632.1992.tb34348.x. [DOI] [PubMed] [Google Scholar]
  • 44.Pedersen CA, Caldwell JD, Walker C, Ayers G, Mason GA. Oxytocin activates the postpartum onset of rat maternal behavior in the ventral tegmental and medial preoptic areas. Behav Neurosci. 1994;108(6):1163–1171. doi: 10.1037//0735-7044.108.6.1163. [DOI] [PubMed] [Google Scholar]
  • 45.Holman SD, Goy RW. Experiential and hormonal correlates of care-giving in rhesus macaques. In: Pryce CR, Martin RD, Skuse D, editors. Motherhood in Human and Nonhuman Primates: Biosocial Determinants. Switzerland: Karger; 1995. [Google Scholar]
  • 46.Williams GL, Gazal OS, Leshin LS, Stanko RL, Anderson LL. Physiological regulation of maternal behavior in heifers: Roles of genital stimulation, intracerebral oxytocin release, and ovarian steroids. Biol Reprod. 2001;65(1):295–300. doi: 10.1095/biolreprod65.1.295. [DOI] [PubMed] [Google Scholar]
  • 47.Bales K, van Westerhuyzen J, Lewis-Reese A, Grotte N, Lanter J, Carter C. Oxytocin has dose-dependent developmental effects on pair-bonding and alloparental care in female prairie voles. Horm Behav. 2007;52(2):274–279. doi: 10.1016/j.yhbeh.2007.05.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Hayes U, De Vries G. Role of pregnancy and parturition in induction of maternal behavior in prairie voles (Microtus ochrogaster) Horm Behav. 2007;51(2):265–272. doi: 10.1016/j.yhbeh.2006.10.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Bakermans-Kranenburg MJ, van Ijzendoorn MH. Oxytocin receptor (OXTR) and serotonin transporter (5-HTT) genes associated with observed parenting. Soc Cogn Affect Neurosci. 2008;3(2):128–134. doi: 10.1093/scan/nsn004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Gordon I, Zagoory-Sharon O, Leckman JF, Feldman R. Oxytocin and the development of parenting in humans. Biol Psychiatry. 2010;68(4):377–382. doi: 10.1016/j.biopsych.2010.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Francis DD, Young LJ, Meaney MJ, Insel TR. Naturally occurring differences in maternal care are associated with the expression of oxytocin and vasopressin (V1a) receptors: Gender differences. J Neuroendocrinol. 2002;14(5):349–353. doi: 10.1046/j.0007-1331.2002.00776.x. [DOI] [PubMed] [Google Scholar]
  • 52.Feldman R, Zagoory-Sharon O, Weisman O, Schneiderman I, Gordon I, Maoz R, et al. Sensitive parenting is associated with plasma oxytocin and polymorphisms in the OXTR and CD38 genes. Biol Psychiatry. 2012;72(3):175–181. doi: 10.1016/j.biopsych.2011.12.025. [DOI] [PubMed] [Google Scholar]
  • 53.Atzil S, Hendler T, Feldman R. Specifying the neurobiological basis of human attachment: brain, hormones, and behavior in synchronous and intrusive mothers. Neuropsychopharmacology. 2011;36(13):2603–2615. doi: 10.1038/npp.2011.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Feldman R, Gordon I, Zagoory-Sharon O. Maternal and paternal plasma, salivary, and urinary oxytocin and parent-infant synchrony: considering stress and affiliation components of human bonding. Dev Sci. 2011;14(4):752–761. doi: 10.1111/j.1467-7687.2010.01021.x. [DOI] [PubMed] [Google Scholar]
  • 55.Wiklund I, Norman M, Uvnas-Moberg K, Ransjo-Arvidson AB, Andolf E. Epidural analgesia: breast-feeding success and related factors. Midwifery. 2009;25(2):e31–e38. doi: 10.1016/j.midw.2007.07.005. [DOI] [PubMed] [Google Scholar]
  • 56.Olza Fernandez I, Marin Gabriel M, Malalana Martinez A, Fernandez-Canadas Morillo A, Lopez Sanchez F, Costarelli V. Newborn feeding behaviour depressed by intrapartum oxytocin: a pilot study. Acta Paediatr. 2012;101(7):749–754. doi: 10.1111/j.1651-2227.2012.02668.x. [DOI] [PubMed] [Google Scholar]
  • 57.Rault JL, Carter CS, Garner JP, Marchant-Forde JN, Richert BT, Lay DC., Jr Repeated intranasal oxytocin administration in early life dysregulates the HPA axis and alters social behavior. Physiol Behav. 2013;112–113:40–48. doi: 10.1016/j.physbeh.2013.02.007. [DOI] [PubMed] [Google Scholar]
  • 58.Tsimis MS, Buckley AP, Nero D, Laurio A. Oxytocin usage for labor induction or augmentation and adverse neonatal outcomes. American College of Obstetricians and Gynecologists 61st Annual Clinical Meeting; New Orleans, LA. 2013. [Google Scholar]
  • 59.Buchanan SL, Patterson JA, Roberts CL, Morris JM, Ford JB. Trends and morbidity associated with oxytocin use in labour in nulliparas at term. Aust N Z J Obstet Gynaecol. 2012;52(2):173–178. doi: 10.1111/j.1479-828X.2011.01403.x. [DOI] [PubMed] [Google Scholar]
  • 60.Kurth L, Haussmann R. Perinatal Pitocin as an early ADHD biomarker: neurodevelopmental risk? J Atten Disord. 2011;15(5):423–431. doi: 10.1177/1087054710397800. [DOI] [PubMed] [Google Scholar]
  • 61.Bell AF, White-Traut R, Rankin K. Fetal exposure to synthetic oxytocin and the relationship with prefeeding cues within one hour postbirth. Early Hum Dev. 2013;89(3):137–143. doi: 10.1016/j.earlhumdev.2012.09.017. [DOI] [PubMed] [Google Scholar]

RESOURCES